Nirmatrelvir with ritonavir, remdesivir, molnupiravir, or monoclonal antibodies after onset of symptoms of COVID-19 may be considered to prevent progression to severe disease in high-risk patients, and remdesivir and monoclonal antibodies may be considered for severe COVID-19.